MIP Technologies AB and Supelco have introduced 'Supelmip', a molecularly imprinted polymer SPE product for the selective extraction of non-steroidal anti-inflammatory drugs (NSAIDs).
Anthony Rees, chief executive officer of MIP Technologies, said: 'Supelmip NSAIDS is an important addition to our portfolio because it targets a critical area of public concern - the increasing appearance of prescription and over-the-counter drugs in environmental water.
'This concern is reflected in the programmes initiated by many governments to monitor national water resources for the presence and concentrations of the most frequently used drugs with the potential for adverse effects.
'This product recognises members of the class of NSAIDs related to ibuprofen and will simplify the analysis of these drugs when present, at even low levels, in natural water samples.' Supelmip was developed for confirmation and quantitation of NSAID drugs in water samples.
The SPE phase has been developed for multi-residue extraction of NSAIDs and has been validated for ibuprofen, diclofenac, naproxen, clofibric acid, celecoxob and piroxicam.
Ibuprofen, diclofenac and naproxen are non-steroidal anti-inflammatory drugs with analgesic and antipyretic activities.
Clofibric acid is an active metabolite of clofibrate, etofibrate and etofyllinclofibrate.
These compounds are used as blood-lipid regulators.
Because of the pharmacological activity of the NSAIDs and the possibility of entry into the domestic water cycle, the concentrations must be accurately quantified in natural water samples.
